Rotigotine

OhioLINK selects Ex Libris Alma and Primo as next library services platform

Retrieved on: 
Wednesday, August 16, 2023
Learning, Ex Libris, Metadata, OhioLINK, Partnership, Senior, CLVT, Teaching, Agriculture, Ohio Department of Education, Research, Kent, Student, Chancellor, ILS, Rotigotine, Kent State University, Faculty, AI, Innovation, University of the Andes Library Services, Library, NYSE, Book, Management

LONDON, Aug. 16, 2023 /PRNewswire/ -- OhioLINK, Ohio's academic library consortium, announces the selection of Ex Libris Alma, part of Clarivate™ (NYSE: CLVT), as the consortium's next shared library services platform. The new cloud-based platform will enhance library user experiences and services, improve efficiencies for day-to-day operations, and streamline collaboration and consortial functionality. The implementation process for OhioLINK's 117 member libraries is expected to take up to two years.

Key Points: 
  • LONDON, Aug. 16, 2023 /PRNewswire/ -- OhioLINK, Ohio's academic library consortium, announces the selection of Ex Libris Alma, part of Clarivate™ (NYSE: CLVT), as the consortium's next shared library services platform.
  • The new cloud-based platform will enhance library user experiences and services, improve efficiencies for day-to-day operations, and streamline collaboration and consortial functionality.
  • In addition to Alma, OhioLINK will implement Primo VE and a suite of related products, including Leganto, Rapido, and Library Mobile, that will enhance services for users, library staff, and administration.
  • OhioLINK's Executive Director Amy Pawlowski led the creation of the consortium's selection and planning process and negotiated the contract for the new library services platform.

OhioLINK selects Ex Libris Alma and Primo as next library services platform

Retrieved on: 
Wednesday, August 16, 2023
Learning, Ex Libris, Metadata, OhioLINK, Partnership, Senior, CLVT, Teaching, Agriculture, Ohio Department of Education, Research, Kent, Student, Chancellor, ILS, Rotigotine, Kent State University, Faculty, AI, Innovation, University of the Andes Library Services, Library, NYSE, Book, Management

LONDON, Aug. 16, 2023 /PRNewswire/ -- OhioLINK, Ohio's academic library consortium, announces the selection of Ex Libris Alma, part of Clarivate™ (NYSE: CLVT), as the consortium's next shared library services platform. The new cloud-based platform will enhance library user experiences and services, improve efficiencies for day-to-day operations, and streamline collaboration and consortial functionality. The implementation process for OhioLINK's 117 member libraries is expected to take up to two years.

Key Points: 
  • LONDON, Aug. 16, 2023 /PRNewswire/ -- OhioLINK, Ohio's academic library consortium, announces the selection of Ex Libris Alma, part of Clarivate™ (NYSE: CLVT), as the consortium's next shared library services platform.
  • The new cloud-based platform will enhance library user experiences and services, improve efficiencies for day-to-day operations, and streamline collaboration and consortial functionality.
  • In addition to Alma, OhioLINK will implement Primo VE and a suite of related products, including Leganto, Rapido, and Library Mobile, that will enhance services for users, library staff, and administration.
  • OhioLINK's Executive Director Amy Pawlowski led the creation of the consortium's selection and planning process and negotiated the contract for the new library services platform.

Parkinson's Disease Market Insights, Epidemiology and Forecasts, 2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 2, 2023
Health, Neurology, SPAC, EU4, Apomorphine, Roche, Holly Steam Combination Company, Pramipexole, A2A, Locomotion, CNM, Cerev Del, Disease, Biogen, Epidemiology, Amneal Pharmaceuticals, Rotigotine, Ropinirole, Dopamine, Amantadine, USD, Movement, Diagnosis, L-DOPA, Parkinson's disease, Acquisition, Patient, AbbVie, United Kingdom, Growth, COMT, Therapy, News, Pharmaceutical industry

The "Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • Parkinson's disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Parkinson's disease market size from 2019 to 2032.
  • The majority of Diagnosed Prevalent Parkinson's Disease patients were estimated in the US followed by EU4 and the UK, and Japan.

Transdermal Skin Patches Market 2022-2028: Featuring InteRNA Technologies, Novartis, Alembic, Pfizer & More - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Pharmaceutical, Health, Medical Supplies, Hormone, Degenerative disease, Rotigotine, BASF SE, Dermatitis, SE, Migraine, Skin, Patient, Medicines and Healthcare products Regulatory Agency, Overactive bladder, Research, Nausea, Vomiting, Pain, Woman, Smoking, Growth, Medication, BASF, Parkinson's disease, Lung cancer, Adhesive, Pharmaceutical industry

The "Transdermal Skin Patches Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transdermal Skin Patches Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, this advancement in patches would drive the global transdermal skin patches market in the forecast period.
  • The global transdermal skin patches market is segmented based on the type and application.
  • Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand the transdermal skin patches market.

CEVA NeuPro-M Edge AI Processor Architecture Recognized at EE Awards Asia 2022

Retrieved on: 
Tuesday, December 13, 2022
Rotigotine, Memory, Halide, Ultra, Image, TensorFlow, DSP, Human, AR, Environment, Edge computing, Interrupt, PyTorch, ONNX, Hillcrest Labs, Architecture, Intelligence, NB, Robotics, Experiential learning, AI, PC, CEVA, Original equipment manufacturer, UWB, Artificial intelligence, SOC, Wi-Fi, Engineering, Semiconductor, Electronics, Machine learning, GNSS, IOT, Algorithm, Medical device, Video game console, Mobile phone, Bluetooth, Multi-chip module

ROCKVILLE, Md., Dec. 13, 2022 /PRNewswire/ -- CEVA, Inc. (NASDAQ: CEVA), the leading licensor of wireless connectivity and smart sensing technologies and co-creation solutions announced today that NeuPro-M AI Processor architecture for artificial intelligence and machine learning (AI/ML) inference workloads has received industry recognition with 'Most Promising Product' at the EE Awards Asia 2022.

Key Points: 
  • 'Creating the future with the electronics industry and changing the world with engineers' is the cited aim of the EE Awards Asia 2022, with the program garnering considerable interest from leading companies across the electronics industry.
  • Ran Snir, Vice President and General Manager of the Vision Business Unit at CEVA, commented: "To be recognized for our NeuPro-M AI/ML architecture, among the engineering community is a big honor for CEVA.
  • Targeting the broad markets of Edge AI and Edge Compute, NeuPro-M is a self-contained heterogeneous architecture.
  • Together with CEVA's multi award-winning neural network AI compiler CDNN and its robust software development environment, NeuPro-M provides a fully programmable hardware/software AI development environment for customers to maximize their AI performance.

Global Parkinson's Disease Analysis Market Spotlight Market Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022
Infectious Diseases, General Health, Pharmaceutical, Health, Parkinson's disease, DMT, Phase, Patent, Pimavanserin, UCB, Patient, L-DOPA, Lewy body, Population, Acadia, Ageing, FDA, Dyskinesia, Delusion, PDP, ANDA, AbbVie, Hallucination, Extrapyramidal system, Laboratory, Standard of care, Government budget balance, Dopamine, Time, HIV disease progression rates, Disease, Roche, Pharmaceutical industry, Pramipexole, Rotigotine, EU, PD

The "Disease Analysis: Parkinson's Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Parkinson's Disease" report has been added to ResearchAndMarkets.com's offering.
  • Duopa is among the most lucrative drugs currently available in the PD market.
  • The procedure, however, is one of the most invasive in this market and comes with the usual risks of surgical complications.
  • Acadia's Nuplazid, the first and only US-approved drug for Parkinson's disease psychosis (PDP), scores well commercially in the publisher's drug assessment model.

DGAP-News: XPhyto Therapeutics Corp.: Parkinson's Generic Transdermal Drug Delivery System

Retrieved on: 
Monday, June 8, 2020
Pharmacology, Health, Dosage forms, Routes of administration, Amines, Phenols, Rotigotine, Thiophenes, Transdermal patch, Generic drug, Transdermal, Dermal patch

VANCOUVER, BC / ACCESSWIRE / June 8, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has finalized the formula for its novel transdermal delivery system ("TDS") for the neurologic drug Rotigotine.

Key Points: 
  • VANCOUVER, BC / ACCESSWIRE / June 8, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has finalized the formula for its novel transdermal delivery system ("TDS") for the neurologic drug Rotigotine.
  • Rotigotine, the active pharmaceutical ingredient, is a generic "off-patent" drug that is typically formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
  • "XPhyto's Parkinson's drug patch is an excellent example of the Company's generic drug delivery strategy whereby approved generic drugs can be delivered using Vektor's novel drug delivery platforms," said Hugh Rogers, CEO of XPhyto.
  • "For both our transdermal patches and oral dissolvable films, we see the generic drug delivery model as a major opportunity for scalable value creation through expedited clinical evaluation and product launch, particularly in Europe."

UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

Retrieved on: 
Monday, July 2, 2018
Medicine, Medical terminology, Health, Parkinson's disease, UCB, Rotigotine, Disease, Chronic condition, Neurological disorder, Gevork Minaskanian

Parkinson's disease (PD) is a chronic, degenerative neurological disease with an estimated prevalence of 1.7% in China in people aged 65 years and older.

Key Points: 
  • Parkinson's disease (PD) is a chronic, degenerative neurological disease with an estimated prevalence of 1.7% in China in people aged 65 years and older.
  • [2]
    With this IDL, NEUPRO is now indicated in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e.
  • NEUPRO is designed to support and improve individual patient treatment experiences for people living with Parkinson's Disease.
  • Alongside approval for NEUPRO, these activities reinforce UCB's ongoing commitment to supporting patients with severe diseases in China.

Quebecers Living with Advanced Parkinson's Disease Now Have Broader Access to NEUPRO® (rotigotine) As Add-On Therapy

Retrieved on: 
Wednesday, June 13, 2018
Parkinson's disease, Geriatrics, Psychiatric diagnosis, RTT, Rotigotine, Parkinson, Chemistry, Medicine, Organic chemistry

According to Nicole Charpentier, Executive Director, Parkinson Quebec, people living with Parkinson's can continue to lead active and fulfilling lives if they are able to manage their symptoms.

Key Points: 
  • According to Nicole Charpentier, Executive Director, Parkinson Quebec, people living with Parkinson's can continue to lead active and fulfilling lives if they are able to manage their symptoms.
  • "For example, problems with balance in Parkinson patients can lead to falls, and problems with swallowing can cause pneumonia if left untreated.
  • That's why Parkinson Quebec congratulates our provincial government for facilitating access to an important treatment option like NEUPRO," says Charpentier.
  • Approved in Canada in 2013, NEUPRO is the first and only Parkinson's "patch" to wear on the skin.